Keep It Simple: EU Consults On Future Design Of EMA’s Fee System
Following a report that identified several shortcomings of the European Medicines Agency fee system, the European Commission has suggested various options to make it sustainable and future-proof.
You may also be interested in...
An international guideline on managing post approval changes to drugs, which was initially criticized because of its incompatibility with legal frameworks in certain ICH regions such as the EU, has been finalized.
Europe’s research-based industry association picks its preferred way forward for simplifying the European Medicines Agency’s fee system.
Reducing dependence on Type II variation fees would free lifecycle management guideline from European Commission’s legal concerns.